Fecal Microbiota Transplantation: Expanding Horizons for Clostridium difficile Infections and Beyond

Antibiotics

Thomas J. Borody²  Debra Peattie¹  Scott W. Mitchell² 

[1]Pleiades Advisors, 13 Oak Meadow Road, Lincoln, MA 01773, USA

[2] E-Mail:

[3]Centre for Digestive Diseases, 1/229 Great North Rd, Five Dock, NSW 2046 Australia

[4] E-Mail:

关键词: Fecal microbiota transplantation;    Clostridium difficile;    inflammatory bowel disease;    IBD;    colitis;    Crohn’s;    irritable bowel;   

DOI  :  10.3390/antibiotics4030254

来源: mdpi

【 摘 要 】

Fecal Microbiota Transplantation (FMT) methodology has been progressively refined over the past several years. The procedure has an extensive track record of success curing Clostridium difficile infection (CDI) with remarkably few adverse effects. It achieves similar levels of success whether the CDI occurs in the young or elderly, previously normal or profoundly ill patients, or those with CDI in Inflammatory Bowel Disease (IBD). While using FMT to treat CDI, however, we learned that using the procedure in other gastrointestinal (GI) diseases, such as IBD without CDI, generally fails to effect cure. To improve results in treating other non-CDI diseases, innovatively designed Randomized Controlled Trials (RCTs) will be required to address questions about mechanisms operating within particular diseases. Availability of orally deliverable FMT products, such as capsules containing lyophilised fecal microbiota, will simplify CDI treatment and open the door to convenient, prolonged FMT delivery to the GI tract and will likely deliver improved results in both CDI and non-CDI diseases.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.